Literature DB >> 17522327

Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp.

Zuleima C Caballero1, Octavio E Sousa, Waldelania P Marques, Amadeo Saez-Alquezar, Eufrosina S Umezawa.   

Abstract

Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas' disease in two studies. In study 1, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from Trypanosoma cruzi epimastigote forms. Kits evaluated in Panama, in study 2, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with T. cruzi trypomastigote excreted-secreted antigens as a reference test to confirm T. cruzi infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17522327      PMCID： PMC2044488          DOI： 10.1128/CVI.00127-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  23 in total

1.  Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits.

Authors:  D A Leiby; S Wendel; D T Takaoka; R M Fachini; L C Oliveira; M A Tibbals
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Diagnostic performance of tests based on Trypanosoma cruzi excreted-secreted antigens in an endemic area for Chagas' disease in Bolivia.

Authors:  Carlos Rodrigo Zarate-Blades; Nelly Bladés; Marilda Savoia Nascimento; José Franco da Silveira; Eufrosina Setsu Umezawa
Journal:  Diagn Microbiol Infect Dis       Date:  2006-10-03       Impact factor: 2.803

3.  Characterization of human infection by Leishmania spp. in the Northwest of Argentina: immune response, double infection with Trypanosoma cruzi and species of Leishmania involved.

Authors:  F M Frank; M M Fernández; N J Taranto; S P Cajal; R A Margni; E Castro; V Thomaz-Soccol; E L Malchiodi
Journal:  Parasitology       Date:  2003-01       Impact factor: 3.234

4.  Action of Trypanosoma rangeli in infections with virulent Trypanosoma cruzi populations.

Authors:  M T Paláu; A J Mejía; U Vergara; C A Zúñiga
Journal:  Mem Inst Oswaldo Cruz       Date:  2003-08-18       Impact factor: 2.743

5.  High prevalence of Trypanosoma rangeli and Trypanosoma cruzi in opossums and triatomids in a formerly-endemic area of Chagas disease in Southeast Brazil.

Authors:  Luis Eduardo Ramirez; Eliane Lages-Silva; Frederico Alvarenga-Franco; Aldo Matos; Nancy Vargas; Octavio Fernandes; Bianca Zingales
Journal:  Acta Trop       Date:  2002-12       Impact factor: 3.112

6.  Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies.

Authors:  Gláucia Elisete Barbosa Marcon; Paula Durante Andrade; Dulcinéia Martins de Albuquerque; Jamiro da Silva Wanderley; Eros Antonio de Almeida; Maria Elena Guariento; Sandra Cecília Botelho Costa
Journal:  Diagn Microbiol Infect Dis       Date:  2002-05       Impact factor: 2.803

7.  An improved serodiagnostic test for Chagas' disease employing a mixture of Trypanosoma cruzi recombinant antigens.

Authors:  Eufrosina S Umezawa; Sueli F Bastos; Jose R Coura; Mariano J Levin; Antonio Gonzalez; Rafael Rangel-Aldao; Bianca Zingales; Alejandro O Luquetti; Jose Franco da Silveira
Journal:  Transfusion       Date:  2003-01       Impact factor: 3.157

8.  Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission.

Authors:  David A Leiby; Ross M Herron; Elizabeth J Read; Bruce A Lenes; Robert J Stumpf
Journal:  Transfusion       Date:  2002-05       Impact factor: 3.157

9.  Trypanosoma rangeli: epimastigote immunogenicity and cross-reaction with Trypanosoma cruzi.

Authors:  A Saldaña; O E Sousa
Journal:  J Parasitol       Date:  1996-04       Impact factor: 1.276

10.  Trypanosoma cruzi in persons without serologic evidence of disease, Argentina.

Authors:  Oscar A Salomone; Ana L Basquiera; Adela Sembaj; Ana M Aguerri; María E Reyes; Mirtha Omelianuk; Ruth A Fernández; Julio Enders; Atilio Palma; José Moreno Barral; Roberto J Madoery
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883
View more
  58 in total

1.  Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods.

Authors:  Juan David Ramírez; Felipe Guhl; Eufrosina Setsu Umezawa; Carlos A Morillo; Fernando Rosas; Jose A Marin-Neto; Silvia Restrepo
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

2.  Mapping antigenic motifs in the trypomastigote small surface antigen from Trypanosoma cruzi.

Authors:  Virginia Balouz; María de Los Milagros Cámara; Gaspar E Cánepa; Santiago J Carmona; Romina Volcovich; Nicolás Gonzalez; Jaime Altcheh; Fernán Agüero; Carlos A Buscaglia
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

3.  Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

Authors:  G F Machado-de-Assis; A R Silva; V A L Do Bem; M T Bahia; O A Martins-Filho; J C P Dias; P Albajar-Viñas; R M Torres; M Lana
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

4.  Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil.

Authors:  Ester C Sabino; Nanci A Salles; Moussa Sarr; Angela M Barreto; Marcio Oikawa; Cláudia D Oliveira; Silvana C Leao; Anna B Carneiro-Proietti; Brian Custer; Michael P Busch
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

5.  Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology.

Authors:  M Carmen Thomas; Ana Fernández-Villegas; Bartolomé Carrilero; Concepción Marañón; Daniel Saura; Oscar Noya; Manuel Segovia; Belkisyolé Alarcón de Noya; Carlos Alonso; Manuel Carlos López
Journal:  Clin Vaccine Immunol       Date:  2011-12-07

6.  The efficacy of L. (L.) chagasi excreted-secreted antigens (ESAs) for visceral leishmaniasis diagnosis is due to low levels of cross-reactivity.

Authors:  Viviana Pinedo-Cancino; Norival Kesper; Clara Lúcia Barbiéri; José Angelo Lauletta Lindoso; Eufrosina Setsu Umezawa
Journal:  Am J Trop Med Hyg       Date:  2013-01-16       Impact factor: 2.345

7.  Detection of Trypanosoma cruzi infection in naturally infected dogs and cats using serological, parasitological and molecular methods.

Authors:  G F Enriquez; M V Cardinal; M M Orozco; A G Schijman; R E Gürtler
Journal:  Acta Trop       Date:  2013-03-13       Impact factor: 3.112

8.  Estimation of sensitivity and specificity of several Trypanosoma cruzi antibody assays in blood donors in Argentina.

Authors:  Mirta C Remesar; Cecilia Gamba; Ivana F Colaianni; Mónica Puppo; Paula A Sartor; Edward L Murphy; Torsten B Neilands; María A Ridolfi; M Susana Leguizamón; Silvina Kuperman; Ana E Del Pozo
Journal:  Transfusion       Date:  2009-11       Impact factor: 3.157

9.  Case Report: Visceral Leishmaniasis Falsely Diagnosed as Q Fever.

Authors:  Ankush Dhariwal; Sarah Jawad; Tihana Bicanic
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

10.  Spatial patterns in discordant diagnostic test results for Chagas disease: links to transmission hotspots.

Authors:  Michael Z Levy; Natalie M Bowman; Vivian Kawai; Joshua B Plotkin; Lance A Waller; Lilia Cabrera; Frank Steurer; Amy E Seitz; Viviana V Pinedo-Cancino; Juan Geny Cornejo del Carpio; Eleazar Cordova Benzaquen; F Ellis McKenzie; James H Maguire; Robert H Gilman; Caryn Bern
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.